Amphastar Pharmaceuticals Inc. (AMPH) Sets New 52-Week High at $21.45
Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) reached a new 52-week high on Tuesday . The company traded as high as $21.45 and last traded at $21.31, with a volume of 1,849,326 shares. The stock had previously closed at $19.00.
A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Needham & Company LLC boosted their target price on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Jefferies Group boosted their target price on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $23.00 target price (up from $22.00) on shares of Amphastar Pharmaceuticals in a report on Wednesday, September 7th. Finally, BMO Capital Markets began coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, June 28th. They issued a “market perform” rating and a $17.00 target price for the company. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Buy” and an average price target of $20.00.
The stock’s 50-day moving average is $18.42 and its 200-day moving average is $15.28. The company has a market cap of $957.92 million, a PE ratio of 68.93 and a beta of 1.83.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/amphastar-pharmaceuticals-inc-amph-sets-new-52-week-high-at-21-45.html
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.22. The firm earned $68 million during the quarter, compared to the consensus estimate of $62.10 million. Amphastar Pharmaceuticals had a return on equity of 4.71% and a net margin of 5.19%. The company’s quarterly revenue was up 26.4% on a year-over-year basis. During the same period last year, the company earned ($0.09) EPS. Analysts forecast that Amphastar Pharmaceuticals Inc. will post $0.37 EPS for the current year.
In related news, Director Stephen B. Shohet sold 48,375 shares of the firm’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $18.24, for a total transaction of $882,360.00. Following the completion of the sale, the director now directly owns 28,653 shares of the company’s stock, valued at approximately $522,630.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William J. Peters sold 2,297 shares of the firm’s stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $17.76, for a total value of $40,794.72. Following the sale, the chief financial officer now directly owns 64,652 shares of the company’s stock, valued at $1,148,219.52. The disclosure for this sale can be found here. Corporate insiders own 29.30% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock worth $109,000 after buying an additional 2,479 shares during the period. Envestnet Asset Management Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the first quarter worth approximately $115,000. BlackRock Group LTD boosted its position in shares of Amphastar Pharmaceuticals by 61.7% in the first quarter. BlackRock Group LTD now owns 11,629 shares of the company’s stock worth $140,000 after buying an additional 4,439 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the first quarter worth approximately $180,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $207,000. Institutional investors own 35.87% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.